Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Yasuo Urata"'
Autor:
Nobuhiko Kanaya, Tomoko Tsumura, Ryoma Sugimoto, Toshiyoshi Fujiwara, Satoru Kikuchi, Masashi Hashimoto, Yasuo Urata, Hiroshi Tazawa, Kento Kumon, Masahiko Nishizaki, Shinji Kuroda, Yuki Hamada, Yoshihiko Kakiuchi, Chiaki Yagi, Shunsuke Kagawa
Publikováno v:
Mol Ther
Extracellular vesicles (EVs) play important roles in various intercellular communication processes. The abscopal effect is an interesting phenomenon in cancer treatment, in which immune activation is generally considered a main factor. We previously
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::694e1e8c95f8e15ca5b3ea376ea13ad5
https://europepmc.org/articles/PMC8530926/
https://europepmc.org/articles/PMC8530926/
Autor:
Yasuaki Yamakawa, Toshiyuki Kunisada, Shunsuke Kagawa, Yusuke Mochizuki, Joe Hasei, Toshifumi Ozaki, Toshinori Omori, Aki Yoshida, Shuhei Osaki, Kazuhisa Sugiu, Tomohiro Fujiwara, Koji Ueda, Hiroya Kondo, Toshiyoshi Fujiwara, Hiroshi Tazawa, Yasuo Urata, Tadashi Komatsubara
Publikováno v:
Cancer chemotherapy and pharmacology. 88(3)
Background Osteosarcoma (OS) is a malignant bone tumor primarily affecting children and adolescents. The prognosis of chemotherapy-refractory OS patients is poor. We developed a tumor suppressor p53–expressing oncolytic adenovirus (OBP-702) that ex
Autor:
Yasuo Urata, Satoru Kikuchi, Masashi Hashimoto, Nobuhiko Kanaya, Hiroyuki Mizuguchi, Kento Kumon, Shunsuke Kagawa, Tomoko Tsumura, Katsuyuki Aoyama, Tetsushi Kubota, Yoshihiko Kakiuchi, Masahiko Nishizaki, Shinji Kuroda, Toshiyoshi Fujiwara, Hiroshi Tazawa, Toshiaki Morihiro
Publikováno v:
Mol Ther
The clinical benefit of monotherapy involving immune checkpoint inhibitors (ICIs) such as anti-programmed death-1 antibody (PD-1 Ab) is limited to small populations. We previously developed a telomerase-specific oncolytic adenovirus, Telomelysin (OBP
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f7e840e5e7e2a07a49da0c071434c45
https://europepmc.org/articles/PMC7054725/
https://europepmc.org/articles/PMC7054725/
Autor:
Toshiyoshi Fujiwara, Toru Kojima, Yuuri Hashimoto, Noriaki Tanaka, Futoshi Uno, Yuichi Watanabe, Shunsuke Kagawa, Ryo Sakai, Yasuo Urata, Yasumoto Yamasaki
Publikováno v:
Molecular Cancer Therapeutics. 9:1884-1893
Multimodal approaches combining drugs that differentially function is the most popular regimen for treating human cancer. Understanding the molecular mechanisms underlying the synergistic, potentiative, and antagonistic effects of drug combinations c
Autor:
Hideki Onimatsu, Masaaki Ouchi, Toru Kojima, Dong Liu, Shinji Kuroda, Yasuo Urata, Yuuri Hashimoto, Toshiyoshi Fujiwara, Yuichi Watanabe
Publikováno v:
Molecular Cancer Therapeutics. 8:980-987
A phase I dose-escalation study of telomerase-specific oncolytic adenovirus, OBP-301 (Telomelysin), is now under way in the United States to assess feasibility and to characterize its pharmacokinetics in patients with advanced solid tumors. The prese